ArticleClinical immunology (Orlando, Fla.)2020
mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome.
Article in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Safety and efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia.Respiratory investigation · 2024Trial
- Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.Cell cycle (Georgetown, Tex.) · 2024Article
- New Markers for Cardiovascular Disease in Psoriatic Patients: Preliminary Study on Monocyte Phenotype, ADAMTS7, and mTOR Activity.Metabolites · 2023Article
- Diabetes and COVID-19: The potential role of mTOR.Diabetes research and clinical practice · 2022Review
- Diffuse Lymphadenopathy Syndrome as a Flare-Up Manifestation in Lupus and Mixed Connective Tissue Disease Following Mild COVID-19.The American journal of case reports · 2021Article
- Rapamycin: Drug Repurposing in SARS-CoV-2 Infection.Pharmaceuticals (Basel, Switzerland) · 2021Review
- In vitro Phenotype Induction of Circulating Monocytes: CD16 and CD163 Analysis.Journal of inflammation research · 2021Article
Corrections and comments
- Comment on
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.